抗炎症治療市場：薬剤クラス別、適応症別、用途別-2025～2030年の世界予測

抗炎症治療市場は、2023年に1,015億3,000万米ドルと評価され、2024年には1,038億5,000万米ドルに達すると予測され、CAGR 4.93％で成長し、2030年には1,422億1,000万米ドルに達すると予測されています。

抗炎症治療市場には、関節炎、喘息、炎症性腸疾患など多くの疾患に共通する経路である炎症を緩和するための治療が含まれます。需要の急増は、高齢化、慢性疾患の有病率の増加、炎症性疾患への早期介入の利点に対する意識の高まりによって促進されています。抗炎症治療は現代医療に不可欠であり、医薬品、生物製剤、バイオシミラーに応用され、エンドユーザーは病院やクリニックから研究機関まで多岐にわたります。この市場の成長は、バイオテクノロジーの進歩、新しい治療法の採用、医療インフラへの世界の投資の増加によって大きな影響を受けています。個別化医療と標的療法は、有効性の向上と副作用の軽減を約束する新たな機会を記載しています。バイオ医薬品部門は、主要地域における有利な規制の枠組みや迅速な医薬品承認プロセスに支えられ、革新と研究のための肥沃な土壌であり続けています。このような機会にもかかわらず、市場は研究開発コストの高さ、規制要件の厳しさ、副作用の可能性といった課題に直面しており、これが市場参入や市場開拓の妨げとなっています。さらに、ジェネリック医薬品や代替医療との競合が市場拡大の脅威となっています。持続的な事業成長のためには、企業はAIを活用した創薬やバイオシミラーの開発といった革新的なアプローチに注力すべきです。さらに、戦略的提携の形成や新興国への投資は、競争上の優位性をもたらす可能性があります。市場の性質はダイナミックであり、科学の進歩や患者中心のアプローチの増加に後押しされています。したがって、企業は機敏に行動し、規制の変化や技術の進歩を注意深くモニタリングして、潜在的な市場の変化をとらえる必要があります。全人的でエビデンス別の治療の重要性を認識し、セグメント横断的なコラボレーションを促進することが、抗炎症治療市場の今後の成長機会を捉える上で極めて重要となります。

市場力学：急速に進化する抗炎症治療市場の主要市場洞察を公開

抗炎症治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネス機会の獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 慢性疾患の世界の多発
  • 炎症性疾患の治療における生物製剤の利用可能性の高まり
  • 炎症性治療の認知度拡大に向けた政府のイニシアティブの高まり
• 市場抑制要因
  • 抗炎症治療に関連する高コスト
• 市場機会
  • 抗炎症治療開発のための研究開発の活発化
  • 抗炎症治療の承認プロセスの上昇
• 市場課題
  • 抗炎症治療に伴う特定の副作用

ポーターのファイブフォース：抗炎症治療市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、抗炎症治療市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：抗炎症治療市場における外部からの影響の把握

外部マクロ環境要因は、抗炎症治療市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：抗炎症治療市場における競合情勢の把握

抗炎症治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：抗炎症治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、抗炎症治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：抗炎症治療市場における成功への道筋を描く

抗炎症治療市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界的に慢性疾患の有病率が高い
    • 炎症性疾患の治療における生物製剤の利用可能性の増大
    • 炎症治療の認知度を高める政府の取り組みが拡大
  • 抑制要因
    • 抗炎症治療に関連する高コスト
  • 機会
    • 抗炎症治療を開発するための研究開発活動の拡大
    • 抗炎症治療の承認プロセスが増加
  • 課題
    • 抗炎症治療に関連する特定の副作用
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 抗炎症治療市場：薬剤クラス別

• イントロダクション
• 抗炎症生物製剤
• コルチコステロイド
• 非ステロイド性抗炎症薬（NSAID）

第7章 抗炎症治療市場：適応症別

• イントロダクション
• 抗炎症性腸疾患
• 関節炎
• 多発性硬化症
• 乾癬
• 呼吸器疾患

第8章 抗炎症治療市場：用途別

• イントロダクション
• 自己免疫
• 炎症性疾患
• 呼吸器疾患

第9章 南北アメリカの抗炎症治療市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋の抗炎症治療市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの抗炎症治療市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbvie, Inc.
• Algen Healthcare Ltd.
• Allegiant Health
• Alvogen
• Amgen Inc.
• Amneal Pharmaceuticals LLC
• Arcutis BIoTherapeutics, Inc.
• Astellas Pharma Inc.
• AstraZeneca PLC
• Bayer AG
• Bristol-Myers Squibb Company
• Clearsynth Labs Limited
• Genentech, Inc. by Roche Group
• GlaxoSmithKline PLC
• Johnson & Johnson Services, Inc.
• Kymera Therapeutics
• Novartis AG
• Pfizer Inc.
• Pharbest Pharmaceuticals, Inc.
• Sanofi Group
• Spectrum Chemical Mfg. Corp.
• Sun Pharmaceutical Industries Ltd.
• Teikoku Seiyaku Co., Ltd.

LIST OF FIGURES

• FIGURE 1. ANTI-INFLAMMATORY THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ANTI-INFLAMMATORY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. ANTI-INFLAMMATORY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ANTI-INFLAMMATORY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ANTI-INFLAMMATORY THERAPEUTICS MARKET DYNAMICS
• TABLE 7. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ANTI-INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RESPIRATORY DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 31. CANADA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 32. CANADA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 33. CANADA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 48. CHINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 49. CHINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 50. CHINA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 51. INDIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 52. INDIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 53. INDIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 103. ITALY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 104. ITALY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 105. ITALY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 115. POLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 116. POLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 117. POLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 118. QATAR ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 119. QATAR ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 120. QATAR ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 148. ANTI-INFLAMMATORY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 149. ANTI-INFLAMMATORY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Anti-Inflammatory Therapeutics Market was valued at USD 101.53 billion in 2023, expected to reach USD 103.85 billion in 2024, and is projected to grow at a CAGR of 4.93%, to USD 142.21 billion by 2030.

The anti-inflammatory therapeutics market encompasses treatments designed to alleviate inflammation, a common pathway in numerous diseases, including arthritis, asthma, and inflammatory bowel diseases. The burgeoning demand is fueled by an aging population, increasing prevalence of chronic diseases, and heightened awareness of the benefits of early intervention in inflammatory conditions. Anti-inflammatory therapeutics are essential in modern medicine, offering applications in pharmaceuticals, biologics, and biosimilars, with end-users ranging from hospitals and clinics to research institutes. Growth in this market is significantly influenced by advancements in biotechnology, the introduction of novel therapeutic methods, and the increasing investment in healthcare infrastructure globally. Personalized medicine and targeted therapies provide an emerging opportunity, promising enhanced efficacy and reduced side effects. The biopharmaceutical sector, supported by favorable regulatory frameworks and expedited drug approval processes in key regions, remains a fertile ground for innovation and research. Despite these opportunities, the market faces challenges such as high R&D costs, strict regulatory requirements, and the potential for adverse drug reactions, which can impede market entry and development. Furthermore, competition from generic drugs and alternative medicine poses a threat to market expansion. For sustainable business growth, companies should focus on innovative approaches like AI-driven drug discovery and the development of biosimilars. Additionally, forming strategic alliances and investing in emerging economies could offer competitive advantages. The nature of the market is dynamic, fueled by scientific advancements and increasing patient-centric approaches. Therefore, businesses should be agile, closely monitoring regulatory changes and technological advancements to seize potential market shifts. Recognizing the importance of holistic, evidence-based treatments, and fostering cross-disciplinary collaborations will be crucial for capturing future growth opportunities in the anti-inflammatory therapeutics market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anti-Inflammatory Therapeutics Market

The Anti-Inflammatory Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • High prevalence of chronic disorders globally
  • Rising availability of biologic drugs for the treatment of inflammatory conditions
  • Growing government initiatives to expand the awareness of inflammatory therapeutics
• Market Restraints
  • High cost associated with anti-inflammatory therapeutics
• Market Opportunities
  • Growing research & development activities to develop anti-inflammatory therapeutics
  • Rising approval process for anti-inflammatory therapeutics
• Market Challenges
  • Certain side effects associated with anti-inflammatory therapeutics

Porter's Five Forces: A Strategic Tool for Navigating the Anti-Inflammatory Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anti-Inflammatory Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anti-Inflammatory Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anti-Inflammatory Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anti-Inflammatory Therapeutics Market

A detailed market share analysis in the Anti-Inflammatory Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anti-Inflammatory Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anti-Inflammatory Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anti-Inflammatory Therapeutics Market

A strategic analysis of the Anti-Inflammatory Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anti-Inflammatory Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbvie, Inc., Algen Healthcare Ltd., Allegiant Health, Alvogen, Amgen Inc., Amneal Pharmaceuticals LLC, Arcutis Biotherapeutics, Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Clearsynth Labs Limited, Genentech, Inc. by Roche Group, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Kymera Therapeutics, Novartis AG, Pfizer Inc., Pharbest Pharmaceuticals, Inc., Sanofi Group, Spectrum Chemical Mfg. Corp., Sun Pharmaceutical Industries Ltd., and Teikoku Seiyaku Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Anti-Inflammatory Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Class, market is studied across Anti-inflammatory Biologics, Corticosteroids, and Non-steroidal Anti-inflammatory Drugs (NSAIDs).
• Based on Indication, market is studied across Anti-inflammatory Bowel Disease, Arthritis, Multiple Sclerosis, Psoriasis, and Respiratory Disease.
• Based on Application, market is studied across Autoimmune, Inflammatory Diseases, and Respiratory Diseases.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. High prevalence of chronic disorders globally
    • 5.1.1.2. Rising availability of biologic drugs for the treatment of inflammatory conditions
    • 5.1.1.3. Growing government initiatives to expand the awareness of inflammatory therapeutics
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with anti-inflammatory therapeutics
  • 5.1.3. Opportunities
    • 5.1.3.1. Growing research & development activities to develop anti-inflammatory therapeutics
    • 5.1.3.2. Rising approval process for anti-inflammatory therapeutics
  • 5.1.4. Challenges
    • 5.1.4.1. Certain side effects associated with anti-inflammatory therapeutics
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Anti-Inflammatory Therapeutics Market, by Drug Class

• 6.1. Introduction
• 6.2. Anti-inflammatory Biologics
• 6.3. Corticosteroids
• 6.4. Non-steroidal Anti-inflammatory Drugs (NSAIDs)

7. Anti-Inflammatory Therapeutics Market, by Indication

• 7.1. Introduction
• 7.2. Anti-inflammatory Bowel Disease
• 7.3. Arthritis
• 7.4. Multiple Sclerosis
• 7.5. Psoriasis
• 7.6. Respiratory Disease

8. Anti-Inflammatory Therapeutics Market, by Application

• 8.1. Introduction
• 8.2. Autoimmune
• 8.3. Inflammatory Diseases
• 8.4. Respiratory Diseases

9. Americas Anti-Inflammatory Therapeutics Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Anti-Inflammatory Therapeutics Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Anti-Inflammatory Therapeutics Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbvie, Inc.
• 2. Algen Healthcare Ltd.
• 3. Allegiant Health
• 4. Alvogen
• 5. Amgen Inc.
• 6. Amneal Pharmaceuticals LLC
• 7. Arcutis Biotherapeutics, Inc.
• 8. Astellas Pharma Inc.
• 9. AstraZeneca PLC
• 10. Bayer AG
• 11. Bristol-Myers Squibb Company
• 12. Clearsynth Labs Limited
• 13. Genentech, Inc. by Roche Group
• 14. GlaxoSmithKline PLC
• 15. Johnson & Johnson Services, Inc.
• 16. Kymera Therapeutics
• 17. Novartis AG
• 18. Pfizer Inc.
• 19. Pharbest Pharmaceuticals, Inc.
• 20. Sanofi Group
• 21. Spectrum Chemical Mfg. Corp.
• 22. Sun Pharmaceutical Industries Ltd.
• 23. Teikoku Seiyaku Co., Ltd.